JPL Wealth Management’s Travere Therapeutics TVTX Stock Holding History

JPL Wealth Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57	Hold	1	–	–	﹤0.01%	1703
2026 Q1	$30	Buy	+1	New	+$30	﹤0.01%	1526

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JPL Wealth Management's TVTX Position: Q2 2026 in Review

JPL Wealth Management held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 1 share worth $57. The position accounts for ﹤0.01% of the portfolio, ranked #1703.

JPL Wealth Management first reported a position in TVTX in Q1 2026 and has held it in 2 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

JPL Wealth Management held 1 share of Travere Therapeutics worth $57 as of Q2 2026.
JPL Wealth Management left its Travere Therapeutics share count unchanged in Q2 2026.
Travere Therapeutics made up ﹤0.01% of JPL Wealth Management's portfolio in Q2 2026, its #1703 holding.
JPL Wealth Management first reported a position in Travere Therapeutics in Q1 2026 and has held it in 2 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on JPL Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.